Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Food Chem Toxicol ; 86: 234-44, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26498410

RESUMO

The safety of fish phosphatidylserine (PS) conjugated to DHA (InCog™) was examined in a series of toxicology studies as first step to support future use in infants and general population using in vitro genotoxicity tests and in a sub-chronic toxicity study with an in-utero exposure phase. PS is a major lipid in the cell membrane, active in various membrane-mediated processes. PS-DHA, present in human milk, has been suggested to be important for early brain development. Rats were exposed to diets containing 1.5%, 3% or 4.5% InCog or two control diets. Parental (F0) animals were fed throughout mating, gestation and lactation. Subsequently, a subchronic, 13-week study was conducted on the F1 animals followed by 4 weeks of recovery. The genotoxicity tests showed no mutagenicity potential. No significant toxicological findings were found in the F0 rats or the F1 pups. In the 13-weeks study, an increase in the presence of renal minimal-mild multifocal corticomedullary mineralization was noted in nine females of the high-dose group. This change was not associated with any inflammatory or degenerative changes in the kidneys. The no-observed-adverse-effect level (NOAEL) in the present study was placed at 3% in the diet (mid-dose group), equivalent to an overall intake of at least 2.1 g InCog/kg bw/day in the F1 generation.


Assuntos
Ácidos Docosa-Hexaenoicos/toxicidade , Exposição Materna , Fosfatidilserinas/toxicidade , Administração Oral , Glândulas Suprarrenais/efeitos dos fármacos , Glândulas Suprarrenais/patologia , Animais , Ácidos Docosa-Hexaenoicos/química , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Masculino , Testes de Mutagenicidade , Tamanho do Órgão , Fosfatidilserinas/química , Gravidez , Efeitos Tardios da Exposição Pré-Natal , Distribuição Aleatória , Ratos , Ratos Wistar , Salmonella typhimurium/efeitos dos fármacos , Salmonella typhimurium/genética , Baço/efeitos dos fármacos , Baço/patologia
2.
Int J Pharm ; 337(1-2): 291-8, 2007 Jun 07.
Artigo em Inglês | MEDLINE | ID: mdl-17300887

RESUMO

The cytotoxicity and physical properties of various submicron O/W emulsions and solid lipid nanoparticles for dermal applications were investigated. Droplet size and zetapotential of submicron emulsions depended on the composition of the cosurfactant blend used. The viability of J774 macrophages, mouse 3T3 fibroblasts and HaCaT keratinocytes was significantly reduced in the presence of stearylamine. Nanoparticles consisting of stearic acid or different kinds of adeps solidus could be manufactured when formulated with lecithin, sodium taurocholate, polysorbate 80 and stearylamine. Survival of macrophages was highly affected by stearic acid and stearylamine. In general a viability of more than 90% was observed when semi-synthetic glycerides or hard fat was employed to formulate nanoparticles.


Assuntos
Portadores de Fármacos , Emulsões , Lipídeos/toxicidade , Nanopartículas , Tensoativos/toxicidade , Administração Cutânea , Aminas/toxicidade , Animais , Células 3T3 BALB , Sobrevivência Celular/efeitos dos fármacos , Gorduras/toxicidade , Fibroblastos/efeitos dos fármacos , Humanos , Queratinócitos/efeitos dos fármacos , Lipídeos/administração & dosagem , Lipídeos/química , Macrófagos/efeitos dos fármacos , Camundongos , Tamanho da Partícula , Fosfatidilcolinas/toxicidade , Fosfatidilserinas/toxicidade , Polissorbatos/toxicidade , Óleo de Soja/toxicidade , Ácidos Esteáricos/toxicidade , Tensoativos/administração & dosagem , Tensoativos/química , Ácido Taurocólico/toxicidade , Água/química
3.
Thromb Haemost ; 77(2): 308-11, 1997 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-9157587

RESUMO

Disseminated intravascular coagulation (DIC) is a frequent complication of septicemia or tissue injury and may be accompanied by elevations of interleukin-6, a mediator of the acute phase response. It is not known whether thrombin or fibrin deposition may directly induce an acute phase response. To study this, we employed a baboon model of in vivo thrombin generation, induced by the administration of purified bovine Factor Xa and phospholipid vesicles. Two Xa/phospholipid dosages were used, a low dosage (2 animals) leading to a rapid 49% decrease in fibrinogen and a high dosage (two injections at 5h interval; 3 animals) leading to complete fibrinogen depletion. Thereafter, fibrinogen levels increased in both treatment groups, reached a maximum of 2.52 +/- 0.23 g/l (mean +/- SE, n = 5; p < 0.01 with respect to basal levels) at day 2, and returned to normal by day seven. In five control (injection of 0.15% NaCl) baboons no significant changes of fibrinogen were observed (maximal values: 1.88 +/- 0.12 g/l). Serum concentrations of C-reactive protein, an acute phase protein, increased from 3.7 +/- 0.4 mg/l to a maximum of 33.0 +/- 7.3 at day one, which was five-fold higher (p < 0.01) than in control animals at day one (6.2 +/- 0.5 mg/l). Transient increases were observed within 6h for interleukin-6 from basal values of 6.2 +/- 1.7 ng/l to peak plasma levels of 42.9 +/- 21.4 ng/l, a value three-fold higher (p = 0.07) than in control animals (14.8 +/- 4.0 ng/l). The preliminary results of this observational study suggest that factor Xa/phospholipid infusion is followed by an acute phase response, leading after one day to significant increases of fibrinogen and of C-reactive protein.


Assuntos
Reação de Fase Aguda/induzido quimicamente , Coagulação Intravascular Disseminada/sangue , Fator Xa/toxicidade , Fosfatidilcolinas/toxicidade , Fosfatidilserinas/toxicidade , Reação de Fase Aguda/sangue , Animais , Biomarcadores , Proteína C-Reativa/análise , Bovinos , Fator Xa/administração & dosagem , Fibrinogênio/metabolismo , Injeções Intravenosas , Interleucina-6/sangue , Papio , Fosfatidilcolinas/administração & dosagem , Fosfatidilcolinas/farmacologia , Fosfatidilserinas/administração & dosagem , Fosfatidilserinas/farmacologia , Trombina/biossíntese
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA